Geneva Advisors’s Aratana Therapeutics, Inc. PETX Stock Holding History

Geneva Advisors’s Portfolio PETX Stock Details PETX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2017 Q2	$579K	Buy	80,118 +2,830	+4%	+$17.4K	0.01%	486
2017 Q1	$410K	Buy	77,288 +3,044	+4%	+$20.6K	0.01%	537
2016 Q4	$533K	Buy	74,244 +3,206	+5%	+$25.9K	0.01%	465
2016 Q3	$665K	Buy	71,038 +1,130	+2%	+$9.38K	0.01%	412
2016 Q2	$442K	Sell	69,908 -1,779	-2%	-$11.4K	0.01%	471
2016 Q1	$396K	Buy	71,687 +41,480	+137%	+$156K	0.01%	481
2015 Q4	$169K	Sell	30,207 -12,867	-30%	-$85K	﹤0.01%	583
2015 Q3	$364K	Buy	43,074 +18,745	+77%	+$317K	0.01%	445
2015 Q2	$368K	Buy	24,329 +8,001	+49%	+$116K	0.01%	487
2015 Q1	$261K	Buy	16,328 +2,970	+22%	+$52.8K	﹤0.01%	544
2014 Q4	$238K	Buy	+13,358	New	+$166K	﹤0.01%	568

Other funds holding PETX

Franklin Resources San Mateo, California $462B AUM 39.16% 1-Year Est. Return

Broadfin Capital New York $747M AUM 100.56% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Janus Henderson Group London $209B AUM 37.72% 1-Year Est. Return

AIC

AWM Investment Company New York $1.15B AUM 201.65% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return

Massachusetts Financial Services Boston, Massachusetts $315B AUM 27.84% 1-Year Est. Return

Alyeska Investment Group Chicago, Illinois $38.9B AUM 28.51% 1-Year Est. Return

William Blair & Company Chicago, Illinois $38.4B AUM 25.71% 1-Year Est. Return

Geneva Advisors's PETX Position: Q2 2017 in Review

Geneva Advisors increased its Aratana Therapeutics, Inc. (PETX) stake by 3.7% in Q2 2017, buying an estimated $17.4K and bringing the position to 80,118 shares worth $579K. The position accounts for 0.01% of the portfolio, ranked #486.

Geneva Advisors first reported a position in PETX in Q4 2014 and has held it in 11 quarters since. The position peaked at $665K in Q3 2016. 105 funds tracked by Wall St. Rank hold PETX as of Q2 2017.

Geneva Advisors held 80,118 shares of Aratana Therapeutics, Inc. worth $579K as of Q2 2017.
Geneva Advisors bought 2,830 Aratana Therapeutics, Inc. shares in Q2 2017, an estimated $17.4K.
Aratana Therapeutics, Inc. made up 0.01% of Geneva Advisors's portfolio in Q2 2017, its #486 holding.
Geneva Advisors first reported a position in Aratana Therapeutics, Inc. in Q4 2014 and has held it in 11 quarters since.
Geneva Advisors's Aratana Therapeutics, Inc. position peaked at $665K in Q3 2016.
105 funds tracked by Wall St. Rank held Aratana Therapeutics, Inc. as of Q2 2017.

Based on Geneva Advisors's 13F filing for Q2 2017, filed 7 Aug 2017.